Transcatheter closure of patent foramen ovale in children with migraine or dizziness
Abstract
UNLABELLED: In recent years, several studies have suggested that transcatheter patent foramen ovale (PFO) closure can relieve migraine and may also improve unexplained dizziness in adults, but evidence in children remains limited. We retrospectively analyzed 95 children (45 boys; age 5.00-18.00 years) who underwent transcatheter PFO closure between June 2019 and September 2024 and were followed for a median of 18.00 months (interquartile range [IQR]: 9.00-27.00). Indications were severe migraine (n = 83; 33 also had dizziness) or recurrent dizziness without migraine (n = 12). Efficacy was evaluated by monthly migraine frequency, Headache Impact Test-6 (HIT-6), Numeric Rating Scale (NRS), and Dizziness Handicap Inventory-Short Form (DHI-S). Safety was assessed by procedural success, fluoroscopy time, dose-area product (DAP), and complications. Closure was successful in 95.96% of cases. Median fluoroscopy time and DAP were 456.00 s (IQR: 341.00-600.00) and 10.73 Gy·cm2 (IQR: 7.16-18.97), respectively. Two transient atrial arrhythmias and one femoral arteriovenous fistula occurred. Among the 83 migraine patients, 23 achieved complete remission and 52 showed partial improvement (overall response 90.36%); monthly migraine frequency, HIT-6 and NRS scores all fell significantly (P < 0.01). DHI-S scores improved both in children with migraine-associated dizziness and in those with isolated dizziness.
CONCLUSION: Transcatheter PFO closure appears safe in children and can alleviate…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 95 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.